RUNX1-RUNX1T1 RQ Kit
Reagent kit for detection and quantification of mRNAs of the chimeric RUNX1-RUNX1T1 gene and ABL reference gene in clinical material by polymerase chain reaction (PCR) with real-time hybridization-fluorescence detection.
The kit of reagents can be used to detect cases of AML associated with RUNX1-RUNX1T1 chromosomal rearrangement, to confirm the diagnosis of AML and to monitor the effectiveness of therapy - to evaluate MRD.
The kit of reagents is designed to conduct a study in a quantitative format for 24 clinical samples in duplicate (132 PCR reactions, including controls).
Additional information about the molecular marker
Chromosomal rearrangement t(8;21)(q22;q22), which results into formation of a chimeric transcript: the product of the fusion between exon 5 of RUNX1 gene (CBFA2, AML1) on chromosome 21q22, and intron 2 of the RUNX1T1 gene (ETO) on chromosome 8q22. It occurs approximately in 8% of AML cases among children and adults under 20 years of age.
Figure 1. Arrangement of the RUNX1-RUNX1T1 chimeric transcript. The binding sites of primers and probes for real-time PCR are marked. The positions of primers and probes are indicated relative to the 5' end of the nucleotide sequences of normal transcripts.
Detection of the RUNX1-RUNX1T1 chimeric transcript is considered a marker of a favorable prognosis for AML patients, thus representing an important target gene for monitoring of minimal residual disease (MRD).
More detailed information on diagnostic approaches, frequency of the study and prognostic value of this testing in leukemias are available on the website of the International Network European Leukemia Net (http://www.leukemia-net.org).
Ordering information:
RUNX1-RUNX1T1 RQ Kit, 24 tests Cat.No RQ-9-24
Additiional reagents:
TriZ Reagent Kit Cat.No TRK-100
ReverZyme Kit Cat.No RT-1
Price: on request
Reagents are for research use only (RUO)